Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

H3K27me3 Loss in Central Nervous System Tumors: Diagnostic, Prognostic, and Therapeutic Implications

11 Oct 2024

Abstract excerpt

Central nervous system (CNS) tumors represent a formidable clinical challenge due to their molecular complexity and varied prognostic outcomes. This review delves into the pivotal role of the epigenetic marker H3K27me3 in the development and treatment of CNS tumors. H3K27me3, specifically the trimethylation of lysine 27 on the histone H3 protein, plays a crucial role in regulating gene expression and maintaining...

Topics

Join the communities discussing this publication.

Chromatin Remodeling and Cancer
Glioma Diagnosis and Treatment
Histone Deacetylase Inhibitors Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39456545
DOI: 10.3390/cancers16203451

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

H3K27me3 Loss in Central Nervous System Tumors: Diagnostic, Prognostic, and Therapeutic ImplicationsPMID 39456545Read ↗

H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.Semantic proximity Read ↗

Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.Semantic proximity Read ↗

Evaluating H3F3A K27M and G34R/V somatic mutations in a cohort of pediatric brain tumors of different and rare histologies.Semantic proximity Read ↗

H3K27M mutant glioma: Disease definition and biological underpinnings.Semantic proximity Read ↗

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.Semantic proximity Read ↗

Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsSemantic proximity Read ↗

WDR82 mediated H3K4me3 is associated with tumor proliferation and therapeutic efficacy in pediatric high-grade gliomasSemantic proximity Read ↗

Histone H3K27M Mutation in Brain Tumors.Semantic proximity Read ↗

Epigenetic mechanisms and therapeutic advances in diffuse midline glioma (Review).Semantic proximity Read ↗

Expanding the spectrum of H3K27-altered gliomas: Hemispheric cases with midline epigenetic signatures.Semantic proximity Read ↗

A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas.Semantic proximity Read ↗

H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic OptionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.